Table 3.

177Lu-J591.

177Lu-J591	Information
	Antibody J591 targets PSMA with long in vivo half-life, weak tissue penetration, and long blood half-life compared to small PSMA-targeting particles.
Treatment Effects
PSA Decrease and OS Extension	Phase I and II trials by Tagawa, Bander et al.: Significant PSA decrease and OS extension in PC patients after 177Lu-J591 treatment.
	PSA decrease, increased survival, higher myelosuppression observed with 177Lu-J591, dose-dependent.
Dosage Fractioning	Fractioning of dosages is safer for similar accumulated dosages with potential efficacies.
Combination with Docetaxel	Functional dosage of 177Lu-J591 with docetaxel: Safety and early therapeutic effect (50% PSA reduction).
Unwanted Side Effects
Thrombocytopenia	- 46.8% patients experienced level 4 thrombocytopenia.
Neutropenia	- 25.5% patients experienced level 4 neutropenia.